Spear Bio Inc., announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Revvity, Inc. (NYSE: RVTY), announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone.

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces the signing of a new development contract with a rare disease biopharmaceutical company.

LNP developers now have access to bench-to-patient lipid synthesis support from a single partner.

AMSBIO has implemented a program of investment to support the students at Penn State Lehigh Valley, part of Pennsylvania State University, in their transformative Course-based Undergraduate Research Experience (CURE) program.

Alfa Chemistry now has an extensive range of products within the pharmaceutical field, including PROTAC building blocks, nucleosides, intermediates and Active Pharmaceutical Ingredients (APIs).

Abselion, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.

Researchers can conduct large-scale transcriptomics and proteomics data analyses on secure, cloud-based platform to accelerate biomarker discovery and drug repurposing applications.

AMSBIO announce a new range of Synthetic Nanodiscs that enable preparation of multi-pass transmembrane proteins in their active form, revolutionizing the future of membrane protein research and drug development.

Flow chemistry specialists Vapourtec have developed the Peptide-Builder, a fully automated, high throughput, benchtop peptide synthesiser, which was launched at the recent TIDES Europe event in Hamburg.